Sphingolipid and Ceramide Metabolism
Three Routes to Ceramide
| Route | Enzymes | Timescale | Product profile |
|---|---|---|---|
| De novo | SPT (SPTLC1/2/3) → 3-ketosphinganine → sphinganine → dihydroceramide (CerS) → ceramide (DES) | Hours | Determined by the CerS isoform expressed |
| Salvage | Ceramide synthases re-acylate sphingosine from sphingolipid breakdown | Minutes to hours | Reflects the sphingosine pool |
| Sphingomyelinase | SMPD1 (acid), SMPD2/3 (neutral) hydrolyse sphingomyelin | Minutes | Sphingomyelin-derived species |
Important distinction. The de novo route and the sphingomyelinase route produce ceramide with different acyl chains and in different compartments. Acid sphingomyelinase acts in lysosomes and at the plasma membrane; the de novo route acts in the ER. A "ceramide increase" measured in a whole-cell extract cannot distinguish them, and the two have different downstream consequences.
Part 1 — The CerS Isoforms
| Isoform | Main product | Tissue | Note |
|---|---|---|---|
| CerS1 | C18:0 | Brain, skeletal muscle | Less studied in metabolic disease |
| CerS2 | C22–C24 | Liver, kidney | Very-long-chain; membrane structural role |
| CerS4 | C18–C22 | Skin, others | |
| CerS5 | C16 | Ubiquitous | Contributes to C16 alongside CerS6 |
| CerS6 | C16 | Ubiquitous, high in metabolic tissues | The isoform most consistently linked to metabolic injury |
Caveat on the C16 story. CerS6 deletion protects against diet-induced metabolic injury in mouse models, and the genetic evidence is stronger than the pharmacological evidence. But CerS5 also produces C16 ceramide, so a CerS6 knockout reduces rather than eliminates the species; total C16 measurement will show a partial effect, and severity of the phenotype may not scale with the residual.
Part 2 — What Each Inhibitor Does
| Agent | Target | Effect | Limitation |
|---|---|---|---|
| Myriocin | Serine palmitoyltransferase | Reduces all de novo sphingolipids | Not ceramide-specific; affects glycosphingolipids and sphingomyelin too |
| Fumonisin B1 | Ceramide synthases | Accumulates sphinganine; reduces complex sphingolipids | Sphinganine is itself bioactive; broad isoform inhibition |
| GW4869 | Neutral sphingomyelinase 2 | Reduces sphingomyelin-derived ceramide | Poor solubility; extracellular vesicle effects |
| Desipramine, amitriptyline | Acid sphingomyelinase | Reduces lysosomal ceramide | Antidepressant off-target effects at effective doses |
| CerS6 knockdown | One isoform | Selective reduction of C16 | Incomplete; compensation by CerS5 |
Readout note. Fumonisin's accumulation of sphinganine is not a side note; it is a mechanism. Studies using fumonisin to "lower ceramide" may be producing a sphinganine-mediated phenotype, and the interpretation requires measuring both species.
Part 3 — Measurement
| Method | What it reports | Requirement |
|---|---|---|
| LC-MS/MS with class-specific internal standards | Individual species, quantitative | Isotope-labelled standards; species separation |
| LC-MS without internal standards | Relative species | Comparability within a run only |
| TLC after lipid extraction | Class-level | Historical; low resolution |
| Antibody-based "ceramide" assays | Bulk signal | Not species-resolved; cross-reactivity |
| Sphingolipid panel kits | Several classes | Verify species coverage and standards |
Important distinction. A total ceramide value is a sum over species that have different physical properties and different biological effects. Reporting it is analogous to reporting total amino acids: technically reproducible, biologically uninformative.
The quantitative standard is a targeted LC-MS/MS panel with isotope-labelled internal standards for each class, reporting at least C14, C16, C18, C20, C22, C24:0 and C24:1, plus dihydroceramides and sphingosine/sphinganine. This is now routine in specialist laboratories and is the difference between a ceramide claim that survives review and one that does not.
Part 4 — Which Ceramide Claim Is Which
| Claim | Minimum evidence | What does not count |
|---|---|---|
| "Ceramide increased" | Species-resolved quantification, at least C16 and C18 separately | Total ceramide |
| "De novo synthesis increased" | Serine or palmitate labelling into ceramide; SPT dependence | Increased CerS expression |
| "Ceramide mediates the phenotype" | Isoform-specific genetic perturbation plus rescue, or a species-specific manipulation | Correlation between ceramide and viability |
| "CerS6-derived C16 is responsible" | CerS6 loss with residual species measured, plus a C16-specific rescue | Total ceramide reduction |
The third row is the difficult one, because there is no clean way to add back a specific ceramide species to a cell. The available approaches are limited: short-chain ceramide analogues (C2, C6) do not partition like endogenous species; ceramide delivery by albumin or liposomes is imprecise. This is why the strongest ceramide papers rely on genetic manipulation of the synthetic route and accept that the rescue is partial.
Part 5 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Serum recorded | Serum contains sphingolipids and lipoproteins |
| Fatty acid supply defined | Palmitate is the substrate for de novo synthesis |
| Serine availability recorded | Serine restriction reduces de novo synthesis independently |
| Species panel reported | Chain length is the variable |
| Dihydroceramide measured | DES activity affects the dihydroceramide/ceramide ratio |
| Timepoint matched to the route | Sphingomyelinase acts in minutes; de novo in hours |
Recurring failures:
- • Total ceramide reported as the finding.
- • Fumonisin used as a ceramide-lowering tool without measuring sphinganine.
- • Myriocin described as a ceramide inhibitor, when it blocks all de novo sphingolipids.
- • Short-chain ceramide analogues treated as equivalent to endogenous species.
- • CerS expression reported as synthesis rate.
- • Serine supply unrecorded in a de novo synthesis claim.
- • Single timepoint that cannot distinguish the sphingomyelinase and de novo routes.
Part 5 — Structural Versus Signalling Ceramide
The same molecule serves two roles, and they are measured and interpreted differently.
| Role | Where | How it is studied | Evidence standard |
|---|---|---|---|
| Structural | Membranes; very-long-chain species | Lipidomics; membrane order; permeability | Composition and physical measurement |
| Signalling | Microdomains; enzyme recruitment | Co-localisation with signalling proteins; PP2A activation | Spatial and functional |
Important distinction. Structural ceramide is abundant and changes slowly; signalling ceramide is a small, compartmentalised pool that can change rapidly without a measurable change in total. A whole-cell lipidomics experiment is well suited to the first and poorly suited to the second, because the signalling pool is a small fraction of the total and is averaged over all membranes.
This is the reason some of the strongest ceramide signalling papers use spatially resolved methods — tagged ceramide-binding domains, or ceramide antibodies validated against a ceramide-deficient background — while some of the strongest metabolic papers use bulk lipidomics. The two literatures describe different pools, and a claim should say which one it concerns.
A practical consequence for design: if the phenotype appears within minutes, it is unlikely to be explained by a change in bulk ceramide, which requires de novo synthesis over hours. Timecourse and route-specific inhibition together identify which pool moved.
Part 6 — Where This Article Connects
Ceramide is one of the toxic species in the lipid pillar, and it sits at the intersection of the sphingolipid module, the fatty acid supply (palmitate and serine are its substrates), and membrane composition through sphingomyelin. The ceramide detection article in this cluster covers the analytical detail; the phospholipid article covers the membrane context in which ceramide acts.
If you need species-resolved sphingolipid measurement with isoform-specific perturbations, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Ceramide species distribution, CerS isoform expression and the balance between routes vary with cell type, substrate supply and stimulus. The associations described here are context-dependent.
A change in total ceramide does not establish which species changed, and a change in a species does not establish that it mediated the phenotype.
Scientific interpretation and experimental design
- • Species, not totals. Chain length is the biological variable.
- • Three routes, three compartments. Whole-cell extracts merge them.
- • Fumonisin accumulates sphinganine. Measure it.
- • Myriocin blocks the whole pathway. Not ceramide-specific.
- • Genetic isoform loss is stronger evidence than pharmacology.
- • Short-chain analogues are not endogenous species.
- • Substrates matter. Palmitate and serine set the rate.
Selected references for further reading
- • Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nature Reviews Molecular Cell Biology. 2018;19:175–191.
- • Turpin-Nolan SM, et al. CerS6-derived C16:0 ceramide promotes the development of obesity and insulin resistance. Cell Metabolism. 2020;31:1–14.
- • Summers SA, Chaurasia B, Holland WL. Metabolic messengers: ceramides in insulin resistance. Nature Metabolism. 2019;1:1051–1064.
- • Merrill AH Jr, et al. Sphingolipid analysis by HPLC–tandem mass spectrometry. Methods in Enzymology. 2005;393:224–243.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »